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Abstract
Background: Differences between the arms in systolic blood pressure (SBP) of 10mmHg have been associated with
an increased risk of mortality in patients with hypertensive and chronic renal disease. For the first time, we examined
these relationships in a non-clinical population.
Design: Cohort study.
Methods: Participants were 4419 men (mean age 38.37 years) from the Vietnam Experience Study. Bilateral SBP and
diastolic BP (DBP), serum lipids, fasting glucose, erythrocyte sedimentation rate, metabolic syndrome, and ankle brachial
index were assessed in 1986.
Results: Ten per cent of men had an interarm difference of 10 and 2.4% of 15mmHg. A 15-year follow-up period
gave rise to 246 deaths (64 from cardiovascular disease, CVD). Interarm differences of 10mmHg were associated with
an elevated risk of all-cause mortality (hazard ratio, HR, 1.49, 95% confidence interval, CI, 1.04–2.14) and CVD mortality
(HR 1.93, 95% CI 1.01–3.69). After adjusting for SBP, DBP, lipids, fasting glucose, and erythrocyte sedimentation rate,
associations between interarm differences of 10mmHg and all-cause mortality (HR 1.35, 95% CI 0.94–1.95) and CVD
mortality (1.62, 95% CI 0.84–3.14) were significantly attenuated.
Conclusions: In this non-clinical cohort study, interarm differences in SBP were not associated with mortality after
accounting for traditional CVD risk factors. Interarm differences might not be valuable as an additional risk factor for
mortality in populations with a low risk of CVD.
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Introduction
A marked diﬀerence in systolic blood pressure (SBP)
between the arms have been linked to subclavian sten-
osis,1,2 atherosclerotic plaque,3 and are most commonly
observed in patients with hypertension,4 diabetes,5 and
chronic renal disease,1 suggesting interarm diﬀerences
are a marker of peripheral vascular disease.6 The pres-
ence of an interarm diﬀerence has been linked to the
delayed diagnosis7 and poor control of hypertension,8
and as such are recommended in screening guidelines
on the assessment of hypertension.9,10 Despite these
associations, few cohorts record information on systolic
blood pressure (SBP) in both arms and as a result asso-
ciations with mortality are unclear. A small number of
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studies have shown diﬀerences of 10mmHg between
the arms in SBP are associated with an increased risk
for all-cause4,6 and cardiovascular disease (CVD) mor-
tality in high risk patients (e.g. hypertension,4,11 chronic
renal disease1). However, owing to a paucity of data,
the extent to which these results are apparent in non-
clinical groups is unclear.
Accordingly, the aim of the present study was to
examine whether interarm diﬀerences in SBP are asso-
ciated with all-cause and CVD mortality over a 15-year
follow-up period in a cohort of middle-aged men.
In addition to examining the link, if any, between inter-
arm diﬀerences in blood pressure and mortality, we also
test whether incorporating information on interarm dif-
ferences into an established risk score for CVD (the
Framingham risk algorithm)12 will improve its predict-
ive capacity for all-cause and CVD mortality.
Methods
Study design and participants
Participants were drawn from the Vietnam Experience
Study. The Vietnam Experience Study is a prospective
cohort of US army veterans that was established in
1983 to compare the health of men who participated
in the Vietnam war against those who did not.13 Brieﬂy,
on 31 December 1983, 18,313 men were drawn ran-
domly from 5 million records of men who served in
Vietnam and elsewhere. Of those men who were
traced, 15,288 (85.6% response) participated in a tele-
phone survey in 1985. A random sample was taken of
telephone survey respondents in 1986 and 4462 (69.3%
of those invited) attended a 3-day medical examination.
Ethical approval for the study protocol was given by
the US Oﬃce for Technology Assessment, the
Department of Health and Human Sciences Advisory
Committee, the Agent Orange Working Group Science
Panel, and a review panel from the US Centers for
Disease Control.
Assessment of interarm differences in blood pressure
Blood pressure was assessed after participants were
seated for at least 2minutes, with a standard mercury
sphygmomanometer. Research nurses were instructed
to ensure each arm was supported during measure-
ments, free of clothing, and only to take measurements
when men appeared relaxed and comfortable.
Measurements were made twice in both arms in an
alternating sequence: right arm, left arm, right arm,
left arm. Standard or large cuﬀs were used as appropri-
ate.14 Interarm diﬀerences in SBP were similar for the
ﬁrst (mean 1.00mmHg; 95% CI 0.76–1.21) and second
pair of assessments (1.05mmHg, 95% CI 0.80–1.29).
Readings were averaged to obtain a mean SBP for
each arm, which was then used to calculate an interarm
diﬀerence (mean of right arm minus mean of left arm).
Assessment of risk factors for CVD mortality
Blood samples were taken in the morning after partici-
pants had fasted from 19:00 the previous day. Levels
of triglycerides, cholesterol fractions, and urinary
creatinine were ascertained using a Ektachem 700
AutoAnalyzer (Eastman Kodak, Rochester,
New York). Serum glucose level was determined with
an adaptation of the glucose oxidase-peroxidase-chro-
mogen-coupled system for glucose determination in
biological ﬂuids. Erythrocyte sedimentation rate
(ESR) was measured using the Westergen method.
Height and weight were measured from which body
mass index was calculated.
We deﬁned the metabolic syndrome using a modiﬁed
version of the Adult Treatment Panel III criteria (using
body mass index 30 kg/m2 instead of waist circumfer-
ence, regarded by the WHO as an acceptable substi-
tute).15,16 Diabetes status was deﬁned as having a
fasting plasma glucose 7.0mmol/l and/or use of medi-
cation for diabetes.17
Hypertension was deﬁned using the JNC 7 cut-oﬀ
points for systolic/diastolic blood pressure 140/
90mmHg, or use of antihypertensive medication.9
Men underwent a separate examination of the periph-
eral arterial system to calculate the ankle brachial index
(ABI) using the Doppler technique. ABI for each leg
was calculated by dividing the ankle systolic pressure
by the higher of the right and left brachial systolic pres-
sures obtained during this examination, and we used
the lower of the left and right leg indices in the analysis,
as an indicator of worse disease. Low ABI was deﬁned
as ABI 0.9.18
Scores for the risk of coronary heart disease at 10
years were calculated using the Framingham equation
with information on age, sex, total cholesterol levels,
high-density lipoprotein (HDL) cholesterol levels,
SBP, and smoking habits.12
Ascertainment of all-cause and CVD mortality
Information on deaths was collected for 15 years after
the 1986 medical examination. Mortality was ascer-
tained using databases supplied by the US army: the
Veterans Administration (Beneﬁciary Identiﬁcation
and Records Locator Subsystem), the Social Security
Administration, the Internal Revenue Service, and the
National Center for Health Statistics (National Death
Index). Events were deﬁned as deaths from all-causes
and those resulting from major CVD (ICD-9: 390–434,
436–448; ICD-10: I00–I78). A previous analysis found
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the standardized (for age, race, and calendar year) mor-
tality ratios of Vietnam Experience Study participants
were comparable to those of an equivalent US male
population.19
Statistical analysis
We compared participants’ characteristics using
ANOVA, chi-squared, and Kruskall–Wallis tests
according to interarm diﬀerences in SBP of 0–4.9,
5–9.9, 10–14.9, and 15mmHg. We examined the pro-
portional hazards assumption graphically for each
interarm diﬀerence in SBP with all-cause and CVD
mortality and found no evidence for violation. We
therefore used Weibull regression analysis to examine
the association between interarm diﬀerences and mor-
tality (for all causes and CVD). This model is a para-
metric form of the Cox proportional hazards model
and accounts for the diﬀering lengths of follow up
among participants. This model also allows researchers
to calculate the risk for mortality during a ﬁxed period
of time (t) as r(t): 1 – exp(–exp(log(t) – Xb)/s), where X is
the vector of risk factors, b is the vector of coeﬃcients,
and s is the estimated scale parameter. This model has
been used previously in the Framingham Heart Study
and to describe the eﬀect of adding new risk factors for
CVD to the Framingham risk score.20
Interarm SBP diﬀerence was ﬁtted as a continuous
term (per 10mmHg) and in separate models, using cate-
gories of <5 vs. 5mmHg, <10 vs. 10mmHg, and
<15 vs. 15mmHg. Hazard ratios and accompanying
95% CIs were sequentially adjusted for a series of
potential confounding factors previously associated
with peripheral vascular disease6 and CVD mortal-
ity.21,22 Adjustments were made for: obesity, smoking
status, units of alcohol per week, and ethnic group
(model 2); model 2 plus mean SBP and DBP (from
the four measurements of SBP and DBP), metabolic
syndrome, triglyceride, HDL cholesterol, glucose,
ESR, and creatinine (model 3); model 3 plus ABI
(0.9 vs >0.9; model 4); and model 4 plus the
Framingham risk score (model 5). We modelled an
interaction between interarm diﬀerences at each cut-
oﬀ point and hypertension status to examine whether
associations were diﬀerent in hypertensive men, as sig-
niﬁcant associations have been found in hypertensive
patients before.4,11
We also calculated the hazards for mortality using a
Weibull model that included the Framingham risk
score and interarm diﬀerences in SBP (at 5, 10,
and 15mmHg) and compared it to a model that
only included the Framingham risk score. We examined
discrimination across the two models by using Harell’s
c-index adjusted for optimism using 100 bootstrap
repetitions;23 an overall (likelihood ratio chi-squared
test) and penalized assessment of model ﬁt (Akaike’s
Information Criterion,24 and the Bayes Information
Criterion).25 We chose these measures of discrimination
rather than the net reclassiﬁcation improvement
index,26 as there was a low number of deaths in men
with high Framingham risk scores.
We then estimated the eﬀect on the hazard ratio of
adjusting for a particular covariate using the following
formula: [(HR adjusted for age and ethnicity  1) 
(HR adjusted for age and ethnicity plus covariate  1)/
(HR adjusted for age and ethnicity  1)]  100. All
analyses were performed with Stata version 11.0 using
two-sided tests with a signiﬁcance level of p< 0.05.
Results
Of the 4462 men eligible for inclusion, 4419 (99.03%)
featured in the analytical sample. The 43 men who
attended the medical examination but were excluded
due to having missing values for some variables had a
lower mean DBP (87.01 vs. 84.09mmHg; p¼ 0.04) and
ESR (41.63 vs. 36.90mm/h; p¼ 0.03) but were similar
in other respects. Supplementary Table 1 (available
online) shows that relative to study members not
selected for the medical examination, men included in
the analytical sample were more likely be obese (12.7
vs. 11.5%), but generally diﬀerences in characteristics
between men included and excluded were small.
Table 1 shows the characteristics of the 4419 partici-
pants. A total of 1667 (37.7%) men had a mean inter-
arm diﬀerence in SBP of 5mmHg, 435 (9.8%) of
10mmHg, 107 (2.4%) of 15mmHg, and 24 (0.5%)
of 20mmHg. The mean interarm diﬀerence in SBP
was 1.03mmHg (95% CI 0.83–1.22), and was higher
in the right arm. Interarm diﬀerences in SBP were posi-
tively associated with mean SBP (0–4.9mmHg mean
122.7 vs. 15mmHg mean 128.25; p< 0.001) and
DBP (0–4.9mmHg mean 83.79 vs. 15mmHg mean
85.71; p¼ 0.01) and diﬀerences of 10 and 15mmHg
were more common in men with hypertension
(p< 0.001), an ABI 0.9 (p¼ 0.01), and those who
were obese (p¼ 0.04). There was, however, no evidence
that interarm diﬀerences were associated with glucose
levels or being deﬁned as having diabetes or metabolic
syndrome (Table 1).
A mean of 14.9 years of follow up (range 0.03–15.00)
gave rise to 246 (5.60%) deaths in total of which 64
(26.01%) were due to CVD. Table 2 shows that in the
unadjusted regression models, the hazard ratios for all-
cause mortality among men with an interarm diﬀerence
in SBP of >5, >10m and> 15mmHg were 1.30 (95%
CI 1.01–1.67), 1.49 (95% CI 1.04–2.14) and 1.37 (95%
CI 0.68–2.77) respectively, with stronger associations
apparent for CVD mortality: for >5mmHg: HR 1.66,
95% CI 1.02–2.71; >10mmHg: HR 1.93, 95%
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CI: 1.01–3.69; >15mmHg HR 2.00, 95% CI 0.63–6.39.
When interarm diﬀerence was ﬁtted as a continuous
term (per 10mmHg), there was positive association
with both all-cause (HR 1.13, 95% CI 1.01–1.27) and
CVD mortality (HR 1.14, 95% CI 0.92–1.40) in the
fully adjusted analysis (Supplementary Table 2).
Following adjustment for established risk factors for
CVD, including the Framingham risk score, the
adjusted hazard ratios (model 5) for interarm diﬀer-
ences of >10mmHg were signiﬁcantly attenuated,
with hazard ratios of 1.35 (95% CI¼ 0.94–1.95) for
all-cause and 1.62 (95% CI 0.84–3.14) for CVD mor-
tality. Supplementary Table 3, shows separate adjust-
ments for factors associated with lifestyle (smoking
status, units of alcohol per week, obesity status) at
the baseline assessment explained little of the attenuat-
ing eﬀect on these associations. In general, adjustment
for hypertension status (all-cause mortality 6–25%),
metabolic syndrome (all-cause mortality 6–22%), and
the Framingham risk score (all-cause mortality 16–
33%) were associated with the largest percentage
reduction in associations between interarm diﬀerences
and mortality.
Harrell’s C-indices indicated a moderate level of dis-
crimination but estimates were not signiﬁcantly diﬀer-
ent across the Framingham risk scores and
Framingham plus interarm diﬀerence models. There
was also little change in the penalized measures of
model ﬁt between the Framingham risk scores and
Framingham plus interarm diﬀerence models
(Supplementary Table 4). Interactions between inter-
arm diﬀerences at 5, 10, and 15mmHg and hyperten-
sion status were also non-signiﬁcant at each cut-oﬀ
point for all-cause and CVD mortality (p> 0.05; data
not tabulated).
Discussion
In a cohort of nearly 4500 men, an interarm diﬀerence
in systolic blood pressure of 10mmHg or more was
associated with an increased risk for CVD and all-cause
mortality. This association was, however, signiﬁcantly
Table 1. Characteristics of participants according to interarm differences in systolic blood pressure in the Vietnam Experience Study
(1986)
Variable
0–4.9mmHg
(n¼ 2752)
5–9.9mmHg
(n¼ 1 232)
10–14.9mmHg
(n¼ 328)
15mmHg
(n¼ 107) ptrend
Age (years) 38.36 2.51 38.27 2.49 38.23 2.57 38.65 2.67 0.37
Systolic blood pressure (mmHg) 122.27 11.57 123.76 12.23 124.27 12.92 128.25 13.85 <0.001
Diastolic blood pressure (mmHg) 83.79 9.20 84.40 9.36 84.98 10.26 85.71 10.86 0.01
Glucose (mmol/l) 5.22 0.93 5.21 0.84 5.34 1.47 5.29 0.49 0.14
Triglycerides (mg/dl) 1.01 (0.70–1.51) 1.01 (0.69–1.46) 1.08 (0.76–1.57) 1.06 (0.75–1.59) 0.08
HDL cholesterol (mg/dl) 1.16 0.33 1.15 0.30 1.13 0.29 1.10 0.31 0.07
Erythrocyte sedimentation rate (mm/h) 36.78 17.15 36.71 17.28 37.38 17.13 40.51 20.64 0.16
Creatinine (mg/dl) 1.11 0.18 1.11 0.18 1.10 0.18 1.13 0.19 0.40
Alcohol intake (units per week) 2.00 (0.00–9.00) 2.00 (0.00–8.00) 2.00 (0.00–9.00) 1.00 (0.00–8.00) 0.24
Ethnic group
White 81.9 (2 253) 83.1 (1 024) 78.4 (257) 83.2 (89)
Black 11.8 (325) 11.5 (142) 12.8 (42) 7.5 (8)
Othera 6.3 (174) 5.4 (66) 8.8 (29) 9.3 (10) 0.15
Hypertension statusb 27.9 (768) 28.6 (352) 36.0 (118) 47.7 (51) <0.001
Ankle brachial index 0.9 3.3 (92) 3.7 (46) 4.3 (14) 9.3 (10) 0.01
Diabetes statusc 2.1 (57) 1.7 (21) 2.4 (8) 0.9 (1) 0.67
Metabolic syndromed 15.8 (435) 14.5 (179) 18.3 (60) 19.6 (21) 0.24
Obesitye 12.1 (334) 12.6 (155) 17.1 (56) 16.8 (18) 0.04
Current smoker 44.1 (1 214) 41.7 (514) 44.8 (147) 35.5 (38) 0.18
Values are mean SD, median (interquartile range), or% (n); aOther group¼Hispanics, Asians, Pacific Islanders, American Indians, and Alaskan Natives;
bNormotensive: systolic blood pressure <140mmHg and diastolic blood pressure <90mmHg; hypertensive: systolic blood pressure >140mmHg or
diastolic blood pressure 8805;90mmHg or on hypertension medication (the Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure criterion) or any hypertension medication; cFasting blood glucose 7.0mmol/l or on
medication for diabetes; dModified version of the Adult Treatment Panel III diagnostic criteria using body mass index 30 kg/m2 instead of waist
circumference; eBody mass index 30 kg/m2; HDL, high-density lipoprotein.
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attenuated after adjustment for established CVD risk
factors. In regard to explanatory factors, smoking
status, units of alcohol per week, and obesity played
little or no part in the associations between interarm
diﬀerences and mortality. ABI, a measure of peripheral
artery disease, had a small but modest eﬀect on the
interarm diﬀerence–mortality association. Adjustment
for hypertension, metabolic syndrome, and in particu-
lar Framingham risk scores at the baseline assessment
had the strongest attenuating eﬀects on the interarm
diﬀerence – mortality association. Consistent with this
ﬁnding, we found interarm diﬀerences did not improve
upon the Framingham risk score in the prediction of
mortality.
We identiﬁed one recent meta analysis6 and two
cohort studies4,27 not included in the meta-analysis
that examined the association between interarm diﬀer-
ences in SBP and all-cause and CVD mortality in
patients with hypertension4 and renal disease.27 A posi-
tive association was reported in the meta analysis
between all-cause mortality and an interarm diﬀerence
of 10mmHg or more in SBP (pooled HR for two
cohorts 1.90 (95% CI 0.8–4.7); 8,11 and two cohorts
not included in this meta analysis reported results of
a similar magnitude.4,27 One cohort of hypertensive
patients reported larger hazards for CVD than all-
cause mortality after 5 (HR 2.8, 95% CI 0.9–9.2)11
and 10 years of follow up (HR 4.2, 95% CI 1.7–
10.8),2–4,7,12 with a similar pattern reported in a
cross-sectional analysis of patients undergoing haemo-
dialysis.27 In contrast to these ﬁndings, we did not ﬁnd
an association between interarm diﬀerences in SBP and
mortality. This inconsistency may in part be attributed
to our deliberate selection of a low-risk cohort charac-
terized by a comparatively low prevalence of hyperten-
sion, metabolic syndrome and other CVD risk factors.
This resulted in a lower event rate and smaller interarm
diﬀerences than have been reported in previous studies
with hypertensive patients.4,11 In support of this asser-
tion, we found a lower proportion of men with interarm
diﬀerences at 10mmHg or more (13.1 vs. 24.0%) and
15mmHg or more (3.9 vs. 9.0%)4 and a lower propor-
tion of deaths in the present cohort (all-cause mortality
5.4 vs. 25.7%).4
Table 2. Unadjusted and adjusted hazard ratios for all-cause and cardiovascular disease mortality at the cut-off points
of 5, 10, and 15mmHg in systolic blood pressure (n¼ 4419)
Model
All deaths (n¼ 246) Cardiovascular deaths (n¼ 64)
HR p-value HR p-value
1
5 1.30 (1.01–1.67) 0.04 1.66 (1.02–2.71) 0.04
10 1.49 (1.04–2.14) 0.03 1.93 (1.01–3.69) 0.04
15 1.37 (0.68–2.77) 0.38 2.00 (0.63–6.39) 0.24
2
5 1.30 (1.01–1.67) 0.04 1.67 (1.02–2.71) 0.04
10 1.43 (1.00–2.06) 0.05 1.84 (0.96–3.53) 0.07
15 1.53 (0.75–3.09) 0.24 2.13 (0.67–6.82) 0.20
3
5 1.28 (0.99–1.65) 0.04 1.61 (0.98–2.64) 0.06
10 1.37 (0.95–1.98) 0.09 1.69 (0.87–3.25) 0.12
15 1.38 (0.67–2.82) 0.37 1.86 (0.57–6.04) 0.30
4
5 1.28 (0.99–1.65) 0.06 1.61 (0.98–2.64) 0.06
10 1.35 (0.94–1.95) 0.11 1.67 (0.87–3.23) 0.12
15 1.28 (0.62–2.62) 0.50 1.85 (0.57–6.04) 0.30
5
5 1.28 (0.99–1.65) 0.06 1.56 (0.95–2.56) 0.08
10 1.35 (0.94–1.95) 0.11 1.62 (0.84–3.14) 0.15
15 1.28 (0.62–2.63) 0.50 1.62 (0.49–5.34) 0.43
Values are hazard ratio (95% confidence interval). Reference category, interarm difference in systolic blood pressure <5, <10, or <15,
depending on the analysis; Model 1, Unadjusted; Model 2, Model 1þ body mass index 30 kg/m2, smoking status, alcohol intake (units
per week), ethnic group; Model 3, Model 2þ systolic blood pressure, diastolic blood pressure, metabolic syndrome, triglycerides, HDL
cholesterol, glucose, erythrocyte sedimentation rate; Model 4. Model 3þ ankle brachial index 0.9; Model 5, Model 4þ Framingham
risk score.
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Despite these diﬀerences in sample characteristics,
one study with hypertensive patients reported large
hazard ratios for the interarm diﬀerence–mortality
association even after adjusting for the Framingham
risk score (diﬀerence of 10mmHg in SBP: HR 2.2;
95% CI 1.4–3.6).4 This suggests a mechanism by
which interarm diﬀerences increase the risk for mortal-
ity which does not involve factors included in the
Framingham risk score; and that this factor was not
present in our cohort. Interarm diﬀerences have been
conceptualized, and are associated with a measure of
peripheral artery disease, the ABI.1,2 However, we
found a low ABI indicative of peripheral artery disease
did not explain associations between interarm diﬀer-
ences and mortality. It is therefore possible that the
cut-oﬀ point we used on the ABI lacks predictive val-
idity that or interarm diﬀerences are indicative of
another comorbidity in hypertensive patients not ade-
quately captured by traditional CVD risk factors.
The strengths of this study are its size, being larger
than previous studies on interarm diﬀerence, and track-
ing of participants over a 15-year period. This allowed
us to evaluate the prognostic value of interarm diﬀer-
ences over a period in middle age where screening for
hypertension typically starts. The non-clinical recruit-
ment meant we could examine associations in a low-risk
population for the ﬁrst time and the comprehensive
measurement of CVD risk factors allowed us to address
concerns that interarm diﬀerences might not add any-
thing over routine CVD risk factor assessment.
This study is not, however, without limitations.
First, the sequential method of recording blood pres-
sure we used may have produced larger interarm diﬀer-
ences than simultaneous readings.28,29 Although, little
diﬀerence has been found between these methods in
estimates of the association of interarm diﬀerences
with ABI, or all-cause mortality.6 Second, we did not
have data on women, and all investigations to date
have been in cohorts in middle to old age;1,4,8,11,27
thus, further testing is needed to conﬁrm associations
in women and diﬀerent age groups. It is also worth
noting that despite not adding to the prediction of mor-
tality, assessment of blood pressure in both arms may
have clinical value by increasing the sensitivity of diag-
nosis and management of hypertension through the use
of measurements from the arm with the highest read-
ing. Additional studies, ideally a controlled clinical
trial, are needed to assess whether incorporating bi-lat-
eral brachial assessments into screening for hyperten-
sion in primary care, would improve the identiﬁcation
and management of individuals at risk for a coronary
heart disease event.
In conclusion, we found that interarm diﬀerences
were associated with survival over a 15-year period in
men with a low risk of CVD, but that these associations
were explained, in part, by traditional CVD risk fac-
tors. As these risk factors are already part of routine
CVD risk screening, interarm diﬀerences may not oﬀer
anything over established risk prediction algorithms,
such as the Framingham risk score, in the prediction
of mortality in populations with a low risk of CVD.
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